Lupin launched hepatic encephalopathy drug Zaxine in Canada

()

Drug Maker Lupin Limited launched hepatic encephalopathy drug Zaxine in Canada under a licensing agreement of US-based Salix Pharmaceuticals Company. In September 2014, the agreement to launch Zaxine drug was signed the agreement and Lupin Pharma Canada Ltd has exclusive rights to sell the drug in Canada. Zaxine is first launch under the agreement with Salix. Lupin has the option to exclusively market, distribute and sell other gastroenterology products in Salix’s Canadian portfolio.

  • Zaxine is the brand name for rifaximin which is used to treat hepatic encephalopathy, a complication of cirrhosis of liver. Zaxine drug is used in long-term treatment for adults in 550mg doses.
  • Zaxine has been approved by Health Canada under priority review for the reduction in risk of overt HE recurrence in patients.
  • Lupin will promote the product to hepatologists and gastroenterologists through its own sales people in Canada for complication of cirrhosis of liver.

- Published/Last Modified on: April 23, 2015